Revolutionizing GI Disease Detection: CapsoVision's 2025 Earnings Call Highlights
On March 26th, 2026, CapsoVision, a pioneering healthcare company, hosted its fourth-quarter and full-year 2025 earnings conference call. The event offered valuable insights into the company's growth momentum, pipeline development, and strategic initiatives.
The call was led by Johnny Wang, President and Chief Executive Officer, along with David Garcia, Senior Vice President of Finance, and Doug Atkinson, Senior Vice President of Sales. CapsoVision's mission remains focused on making early, accurate, and accessible GI disease detection available to patients worldwide.
One of the key highlights from 2025 was the company's increased commercial momentum for its flagship product, CapsoCam Plus. This small-bowel capsule endoscopy solution delivered approximately 15% year-over-year revenue growth and a 21% increase in new account generation, reflecting continued adoption across both new and existing customers.
As of December 31, 2025, more than 161,000 patients have been imaged with CapsoCam Plus. This growing installed base, combined with strong physician engagement, reinforces the value of CapsoVision's differentiated platform. The company's cloud-based architecture serves as the foundation for its AI strategy, allowing for the development and deployment of AI models that improve diagnostic accuracy, reduce reading time, and enhance clinical efficiency.
On the pipeline development front, CapsoVision has continued to make exciting advances. The company submitted a 510(k) application for its AI-assisted reading module, designed to enhance lesion detection and streamline physician review. This represents an important step in further differentiating the core platform and expanding its clinical and economic value.
The company is also advancing its CapsoCam Colon program, with a refined development strategy prioritizing their second-generation capsule. Building on insights gained from FDA interactions, CapsoVision aims to deliver a more competitive and clinically differentiated solution at launch. This disciplined approach enables the company to bring a stronger product to market, rather than iterating post-clearance.
CapsoVision's focus on innovation and customer engagement has positioned the company for continued success in 2026. As the healthcare landscape continues to evolve, CapsoVision remains committed to delivering cutting-edge solutions that improve patient outcomes and enhance clinical efficiency.
